BB Biotech AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
For the nine months, revenue was CHF 0.622 million compared to CHF 1.26 million a year ago. Net loss was CHF 315.72 million compared to CHF 322.65 million a year ago. Basic loss per share from continuing operations was CHF 5.76 compared to CHF 5.86 a year ago. Diluted loss per share from continuing operations was CHF 5.76 compared to CHF 5.86 a year ago.